NewGenIvf Group Net Income Over Time
| NIVF Stock | 0.80 0.07 9.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NewGenIvf Group Performance and NewGenIvf Group Correlation. NewGenIvf | Build AI portfolio with NewGenIvf Stock |
Can Health Care Providers & Services industry sustain growth momentum? Does NewGenIvf have expansion opportunities? Factors like these will boost the valuation of NewGenIvf Group. Anticipated expansion of NewGenIvf directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating NewGenIvf Group demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share 4.2 K | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Understanding NewGenIvf Group requires distinguishing between market price and book value, where the latter reflects NewGenIvf's accounting equity. The concept of intrinsic value - what NewGenIvf Group's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push NewGenIvf Group's price substantially above or below its fundamental value.
It's important to distinguish between NewGenIvf Group's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewGenIvf Group should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NewGenIvf Group's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare NewGenIvf Group and related stocks such as Scworx Corp, Hepion Pharmaceuticals, and ZyVersa Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WORX | (386.5 K) | (386.5 K) | (386.5 K) | (386.5 K) | (386.5 K) | (386.5 K) | (4.2 M) | (12 M) | (14.6 M) | (11.5 M) | (7.4 M) | (3.8 M) | (1.8 M) | (4 M) | (1.1 M) | (1.3 M) | (1.4 M) |
| ZVSA | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (8.1 M) | (14 M) | (98.3 M) | (9.4 B) | (8.5 B) | (8 B) |
| CDT | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (4.9 M) | (535 K) | (17.8 M) | 237.5 M | 249.4 M |
| IVF | (7.4 K) | (797.5 K) | (666.5 K) | (760.7 K) | (1.7 M) | (5 M) | (2.1 M) | (702.2 K) | (3.1 M) | (2.2 M) | (8.3 M) | (6.7 M) | (10.9 M) | (8 M) | (9.1 M) | (8.2 M) | (7.8 M) |
| COCH | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (8.7 M) | (15.9 M) | (29.9 M) | (20.8 M) | (18.7 M) | (19.7 M) |
| CCM | 79.1 M | (215 M) | 123.2 M | 85.9 M | 124.7 M | (78.3 M) | (261.9 M) | (284.3 M) | (234.9 M) | (307 M) | (404 M) | (271.4 M) | (489.7 M) | (297.7 M) | (308.2 M) | (277.4 M) | (263.5 M) |
| XAGE | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (9.1 M) | (15.4 M) | (10.4 M) | (9.3 M) | (9.8 M) |
NewGenIvf Group and related stocks such as Scworx Corp, Hepion Pharmaceuticals, and ZyVersa Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in NewGenIvf Group financial statement analysis. It represents the amount of money remaining after all of NewGenIvf Group Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| NewGenIvf Group Limited | NIVF |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | PS Tower,13th Floor, |
| Exchange | NASDAQ Exchange |
null 0.8
Check out NewGenIvf Group Performance and NewGenIvf Group Correlation. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
NewGenIvf Group technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.